Press Release

Non-muscle Invasive Bladder Cancer Therapeutics Market Size, Share, Key Players Overview and Geographical Outlook 2026

Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Growth Rate by Top Continents Forecast till 2026

The increasing incidence of bladder cancer around the world is a factor driving the global non-muscle invasive bladder cancer therapeutics market, says Fortune Business Insights in a report, titled “Non-muscle Invasive Bladder Cancer Therapeutics Market Size, Share and Global Trend By Stage (Carcinoma in Situ (CIS), T1 Stage, Ta Stage), By Treatment (Immunotherapy, Chemotherapy, Others), By Route of Administration (Systemic, Intravesical, Others), By Distribution Channel ( Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography Forecast till 2026.”  Advancements in healthcare services are predicted to aid the growth of the global non-muscle invasive bladder cancer therapeutics market during the forecast period.

Get Sample PDF:

https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/non-muscle-invasive-bladder-cancer-therapeutics-market-101120

Top Leaders Overview:

Some of the leading companies in the global Non-Muscle Invasive Bladder Cancer Therapeutics Market are

  • Pfizer
  • GlaxoSmithKline
  • Celgene Corporation
  • Sanofi S.A, F
  • Hoffmann-La Roche
  • Novartis International AG
  • Eli Lilly
  • AstraZeneca
  • Bristol-Myers Squibb

Rising Prevalence Of Bladder Cancer Will Propel Growth

The increasing prevalence of bladder cancer is expected to boost global non-muscle invasive bladder cancer therapeutics market growth. The advancement in health care services along with the growing technological advancements in the bladder cancer detection system. This factor has led to higher demand for the treatment of bladder cancer, which in turn will stimulate non-muscle invasive bladder cancer therapeutics market growth during the forecast period. Furthermore, the rising adoption of smoking and growing geriatric population is likely to accelerate non-muscle invasive bladder cancer therapeutics market revenue. Furthermore, the pivotal phase 2 study is expected to augment non-muscle invasive bladder cancer therapeutics market growth.

For instance, Anchiano Therapeutics, announced the initiation of Codex, the pivotal Phase 2 study of inodiftagene vixteplasmid (BC-819), first-in-class gene therapy for patients with non-muscle invasive bladder cancer (NMIBC). Moreover, the commercialization of nadofaragene firadenovec/Syn3 (rAd-IFN/Syn3) is likely to favor growth of the global non-muscle invasive bladder cancer therapeutics market.

For instance, Ferring Pharmaceuticals signed an agreement to commercialize nadofaragene firadenovec/Syn3 (rAd-IFN/Syn3), for the patients with high-grade non-muscle invasive bladder cancer (NMIBC), who are unresponsive to Bacillus Calmette-Guérin (BCG) therapy. However, the high cost of bladder cancer treatment is expected to restrict the growth of the global non-muscle invasive bladder cancer therapeutics market. In addition, many side effects associated with the treatment such as nausea, a low-grade fever, chills, kidney damage will further hamper non-muscle invasive bladder cancer therapeutics market growth

Browse Complete Report:

https://www.fortunebusinessinsights.com/industry-reports/non-muscle-invasive-bladder-cancer-therapeutics-market-101120

Increasing Geriatric Population Will Enable Growth In North America And Europe

Geographically, the global non- muscle-invasive bladder cancer therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Presently North America followed by Europe are projected to be the two largest markets for non- muscle-invasive bladder cancer therapeutics and are expected to dominate the global non- muscle-invasive bladder cancer therapeutics market during the forecast period due to the increasing prevalence of bladder cancer.

The rising geriatric population and growing investment in the development of new drugs to treat non-muscle invasive bladder cancer will also contribute to growth. Asia Pacific is the expected to grow at a faster pace owing to surge in the number of smokers leading to the increasing prevalence of bladder cancer. Further, rising awareness about cancer diagnosis and growing demand for the new and advanced treatment and therapies will augment growth in Asia Pacific. The rise in healthcare expenditure and developing healthcare infrastructure will further boost the of the global non-muscle invasive bladder cancer therapeutics market shares in the region.

Some of the major companies that are present in the global non- muscle-invasive bladder cancer therapeutics market are Pfizer, Inc., GlaxoSmithKline, Celgene Corporation, Sanofi S.A, F. Hoffmann-La Roche, Novartis International AG, Eli Lilly and Co., AstraZeneca plc., Bristol-Myers Squibb and others.

Speak to Analyst:

https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/non-muscle-invasive-bladder-cancer-therapeutics-market-101120

View Related Reports:

Infant Formula Market Size to Reach USD 103.75 Billion by 2026 | Fortune Business Insights

In-vitro Diagnostics Market To Exhibit a CAGR of 4.5%; Adoption Of New Techniques For Rapid Disease Diagnosis Will Encourage Growth, says Fortune Business Insights

Probiotics Market Size to reach USD 74.69 Billion by 2025 at 7.3% CAGR | Exclusive Report by Fortune Business Insights

Tags

Jesus Rust

Jesus is leading the environment column. He is a very renowned environmentalist and has worked in many projects, some of which are based in faraway lands too. He always encourages environment conservation and sometimes keeps small group talks about the concerns. His writing and editing skills act the cheery on the top of the cake.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close